Fidelity Investments
GALT icon

Fidelity Investments’s Galectin Therapeutics GALT Stock Holding History

Fidelity Investments’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$61K Buy
13,141
+154
+1% +$399 ﹤0.01% 4227
2026
Q1 		$36.2K Buy
12,987
+180
+1% +$548 ﹤0.01% 4262
2025
Q4 		$53.3K Buy
12,807
+100
+0.8% +$527 ﹤0.01% 4076
2025
Q3 		$53.8K Buy
12,707
+26
+0.2% +$98 ﹤0.01% 3938
2025
Q2 		$26.8K Buy
12,681
+1,811
+17% +$2.71K ﹤0.01% 4172
2025
Q1 		$13.3K Buy
10,870
+9,049
+497% +$12.7K ﹤0.01% 4388
2024
Q4 		$2.35K Buy
1,821
+1,639
+901% +$3.93K ﹤0.01% 4798
2024
Q3 		$501 Buy
+182
New +$447 ﹤0.01% 4968
2023
Q2 		– Sell
-3,200
Closed -$6.72K – 5459
2023
Q1 		$6.72K Buy
+3,200
New +$5.17K ﹤0.01% 4285
2022
Q3 		– Sell
-4,000
Closed -$5K – 5073
2022
Q2 		$5K Buy
4,000
+1,975
+98% +$2.84K ﹤0.01% 4310
2022
Q1 		$3K Buy
2,025
+1,980
+4,400% +$3.83K ﹤0.01% 4562
2021
Q4 		$0 Hold
45
– – ﹤0.01% 4565
2021
Q3 		$0 Buy
45
+44
+4,400% +$149 ﹤0.01% 4600
2021
Q2 		$0 Sell
1
-1,499
-100% -$5.33K ﹤0.01% 4477
2021
Q1 		$3K Buy
+1,500
New +$3.36K ﹤0.01% 3637
2019
Q4 		– Sell
-16
Closed – – 3953
2019
Q3 		$0 Hold
16
– – ﹤0.01% 3935
2019
Q2 		$0 Buy
+16
New +$69 ﹤0.01% 3889
2019
Q1 		– Sell
-800
Closed -$3K – 3814
2018
Q4 		$3K Hold
800
– – ﹤0.01% 3270
2018
Q3 		$5K Buy
+800
New +$4.4K ﹤0.01% 3252

Other funds holding GALT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
WANY
Wealthspire Advisors (New York) New York $18.2B AUM 21.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Fidelity Investments's GALT Position: Q2 2026 in Review

Fidelity Investments increased its Galectin Therapeutics (GALT) stake by 1.2% in Q2 2026, buying an estimated $399 and bringing the position to 13,141 shares worth $61K. The position accounts for ﹤0.01% of the portfolio, ranked #4227.

Fidelity Investments first reported a position in GALT in Q3 2018 and has held it in 19 quarters since. 98 funds tracked by Wall St. Rank hold GALT as of Q2 2026.

  • Fidelity Investments held 13,141 shares of Galectin Therapeutics worth $61K as of Q2 2026.
  • Fidelity Investments bought 154 Galectin Therapeutics shares in Q2 2026, an estimated $399.
  • Galectin Therapeutics made up ﹤0.01% of Fidelity Investments's portfolio in Q2 2026, its #4227 holding.
  • Fidelity Investments first reported a position in Galectin Therapeutics in Q3 2018 and has held it in 19 quarters since.
  • 98 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q2 2026.

Based on Fidelity Investments's 13F filing for Q2 2026, filed 13 Aug 2026.